Brokerages have assigned a consensus rating of “Buy” to Fusion Pharmaceuticals Inc. (NASDAQ:FUSN).
According to Bloomberg, the seven rating agencies presently keeping an eye on Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) have collectively provided the company with a recommendation …